Profile cover photo
Profile photo
iHealthcareAnalyst, Inc.
Healthcare Market Research & Consulting Services
Healthcare Market Research & Consulting Services
About
Posts

Post has attachment
Global Nebulizer and Spacer for pMDI Devices Market US$ 1.7 Billion by 2021
The global nebulizer and spacer for pMDI devices market expected to reach US$ 1.7 billion by 2021, growing at CAGR 6.5% over the forecast period 2017-2021.
The global nebulizer and spacer for pMDI devices market segmentation is based on device type (nebulizer, spacer for pMDIs), and by geography (region and country). The report provides market size (Revenue US$ Million) and volume (number of units in thousand) from 2014 to 2021, market share analysis, growth trends and forecast (CAGR%, 2017 to 2021).
Drug delivery mechanisms using aerosols are an integral part of the treatment of respiratory disorders (e.g. asthma, obstructive lung disorders, cystic fibrosis, pulmonary arterial hypertension, infectious pulmonary disease). Inhalation drug delivery devices such as MDIs, DPIs and nebulizers have been a large part of asthma/ COPD inhaler success over the last 10 years.
Visit Nebulizer and Spacer for pMDI Devices Market by Device Type (Nebulizer, Spacer for MDIs), by Geography (North America, Europe, Asia Pacific, Latin America, RoW), Key Competitors, Distribution Channels and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/
Visit Inhalation Drug Delivery Devices Market by Device Type (Asthma Devices, COPD Devices), and Technology (Dry Powder Inhalers; Metered Dose Inhalers – Breath-actuated MDIs, Spacers for MDIs; Nebulizers) and Forecast 2017-2021 https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/
The global nebulizer and spacer for pMDI devices market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global nebulizer and spacer devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global nebulization devices market include Philips Respironics, Omron Healthcare, Graham-Field Health Products, Inc., PARI Respiratory Equipment, Inc., and Others (Aerogen, Allied Healthcare Products, GE Healthcare, Drive Medical/DeVilbiss Healthcare, ResMed, Salter Labs Inc., etc.).
Major players operating in the global spacer for pMDI devices for pMDIs (open tube and reverse-flow) market include Monaghan Medical Corporation, Chiesi Farmaceutici S.p.A., Respiratory Delivery Systems, Inc., Merck & Co., Inc., Smiths Medical, Inc., Philips Respironics (Respironics, Inc.), and Destal Industries, Inc.
Major manufacturing companies operating in global Valved Holding Chambers (VHCs) market include GlaxoSmithKline, Monaghan Medical Corporation, AstraZeneca, SunMed, Mylan Specialty L.P., FSC Pediatrics, AM Systems, Thayer Medical, Philips Respironics, Salter Labs, Merck & Co., Inc., Menarini Group, PARI Respiratory Equipment, Inc., nSpire Health Ltd., Rhône-Poulenc S.A., Laboratory Aldo-Union, S.A., Medical Developments International, and Henry Ford Allegiance Health.
The report also includes information on regulatory requirement, medical insurance, and description on traditional and emerging distribution channels for global nebulizer and spacer devices market.
Device Type
1.1. Nebulizer
1.2. Spacer for MDIs

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Nebulization Devices Market
3.1.1. Aerogen
3.1.2. Allied Healthcare Products
3.1.3. Drive Medical/DeVilbiss Healthcare
3.1.4. GE Healthcare
3.1.5. Graham-Field Health Products, Inc.
3.1.6. Omron Healthcare
3.1.7. PARI Respiratory Equipment, Inc.
3.1.8. Philips Respironics
3.1.9. ResMed
3.1.10. Salter Labs Inc.
3.2. Spacer for pMDI Devices (Open Tube and Reverse-Flow) Market
3.2.1. Chiesi Farmaceutici S.p.A.
3.2.2. Destal Industries, Inc.
3.2.3. Merck & Co., Inc.
3.2.4. Monaghan Medical Corporation
3.2.5. Philips Respironics (Respironics, Inc.)
3.2.6. Respiratory Delivery Systems, Inc.
3.2.7. Smiths Medical, Inc.
3.3. Valved Holding Chambers (VHCs) Market
3.3.1. AM Systems
3.3.2. AstraZeneca
3.3.3. FSC Pediatrics
3.3.4. GlaxoSmithKline
3.3.5. Henry Ford Allegiance Health
3.3.6. Laboratory Aldo-Union, S.A.
3.3.7. Medical Developments International
3.3.8. Menarini Group
3.3.9. Merck & Co., Inc.
3.3.10. Monaghan Medical Corporation
3.3.11. Mylan Specialty L.P.
3.3.12. nSpire Health Ltd.
3.3.13. PARI Respiratory Equipment, Inc.
3.3.14. Philips Respironics
3.3.15. Rhône-Poulenc S.A.
3.3.16. Salter Labs
3.3.17. SunMed
3.3.18. Thayer Medical

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/

Global Cancer Molecular Diagnostics Market US$ 21.7 Billion by 2021
The global cancer molecular diagnostics market expected to reach US$ 21.7 billion by 2021, growing at CAGR 44% over the forecast period 2017-2021.
Diagnostic tests are at the forefront of medical innovation, providing vital insights into patient health and transforming cancer care. Molecular diagnostics have transformed the way to approach cancer care, and promise to be a critical contributor to further progress. It can help differentiate cancer from benign tumors (i.e., growths that are not harmful) and can further help identify the type of tissue in which the cancer originated (e.g., breast, lung, skin, etc.).
Visit Cancer Molecular Diagnostics Market by Technology Platform (RT-PCR, DNA Microarray, Lab-On-A-Chip (LOAC), Next Generation Sequencing (NGS), Multiplex Conventional, Next Generation Capture, Protein Microarray, Others); by Application or Cancer Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Precancer, Prostate Cancer, Melanoma, Leukemia, Lymphoma, Pancreatic Cancer, Bladder Cancer, Chest Cancer, Brain Cancer, Thyroid Cancer, Kidney Cancer, Ovarian Cancer, Stomach Cancer, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/
The global cancer molecular diagnostics market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global cancer molecular diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global cancer molecular diagnostics market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global cancer molecular diagnostics market and profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Cepheid, Inc., Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen, Siemens Healthcare, and others.

1. Technology Platform
1.1. RT-PCR
1.2. DNA Microarray
1.3. Lab-On-A-Chip (LOAC)
1.4. Next Generation Sequencing (NGS)
1.5. Multiplex Conventional
1.6. Next Generation Capture
1.7. Protein Microarray
1.8. Others

2. Application (Cancer Type)
2.1. Breast Cancer
2.2. Colorectal Cancer
2.3. Cervical Cancer
2.4. Lung Cancer
2.5. Precancer
2.6. Prostate Cancer
2.7. Melanoma
2.8. Leukemia
2.9. Lymphoma
2.10. Pancreatic Cancer
2.11. Bladder Cancer
2.12. Chest Cancer
2.13. Brain Cancer
2.14. Thyroid Cancer
2.15. Kidney Cancer
2.16. Ovarian Cancer
2.17. Stomach Cancer
2.18. Others

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Asia Pacific (Japan, China, India, Rest of APAC)
3.4. Latin America (Brazil, Mexico, Rest of LA)
3.5. Rest of the World

4. Company Profiles
4.1. Abbott Laboratories
4.2. Becton, Dickinson and Company
4.3. Cepheid, Inc.
4.4. Hoffmann-La Roche Ltd.
4.5. Hologic, Inc.
4.6. Qiagen
4.7. Siemens Healthcare

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/

Global Blood Cancer Molecular Diagnostics Market US$ 3.8 Billion by 2021
The global blood cancer molecular diagnostics market expected to reach US$ 3.8 billion by 2021, growing at CAGR 51.7% over the forecast period 2017-2021.
Acute lymphoblastic leukemia (ALL) is characterized by the production of immature white blood cells, whereas Chronic lymphocytic leukemia (CLL), leukemia of the B-cells is the most common form of leukemia in adults. Treatments include chemotherapy, biological agents, and transplant. Lymphomas are a broad group of blood cancers that affect T and B cell lymphocytes. Treatments of lymphomas include chemotherapy, radiation therapy, and bone marrow transplantation. Molecular diagnostic tests detect mutations in DNA or RNA that are associated with blood cancers. The Federal Drug Administration (FDA), Centers for Medicare & Medicaid Services, and Clinical Laboratory Improvement Act (CLIA) regulate clinical molecular tests like all other clinical laboratory tests.

Visit Blood Cancer Molecular Diagnostics Market by Technology Platform (RT-PCR, DNA Microarray, Lab-On-A-Chip (LOAC), Next Generation Sequencing (NGS), Multiplex Conventional); by Application or Cancer Type (Leukemia, Lymphoma) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/
The global blood cancer molecular diagnostics market segmentation is based on technology platform (RT-PCR, DNA microarray, Lab-On-A-Chip (LOAC), next generation sequencing (NGS), multiplex conventional); by application or cancer type (leukemia, lymphoma).
The global blood cancer molecular diagnostics market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global blood cancer molecular diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global blood cancer molecular diagnostics market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global blood cancer molecular diagnostics market and profiled in this report include Asuragen, Biological Dynamics, BlueGnome (Illumina), Cancer Genetics, Inc., Cepheid, Inc., Clarient, Inc. (GE Healthcare), Combimatrix Corp., Foundation One, Insight Genetics, Inc., InVivoScribe Technologies, Inc., Ipsogen (Qiagen), Münchner Leukämie Labor, Sequenta, Inc., Signature Genomics, and SkylineDx BV.

1. Technology Platform
1.1. RT-PCR
1.2. DNA Microarray
1.3. Lab-On-A-Chip (LOAC)
1.4. Next Generation Sequencing (NGS)
1.5. Multiplex Conventional

2. Application (Cancer Type)
2.1. Leukemia
2.2. Lymphoma

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Asia Pacific (Japan, China, India, Rest of APAC)
3.4. Latin America (Brazil, Mexico, Rest of LA)
3.5. Rest of the World

4. Company Profiles
4.1. Asuragen
4.2. Biological Dynamics
4.3. BlueGnome (Illumina)
4.4. Cancer Genetics, Inc.
4.5. Cepheid, Inc.
4.6. Clarient, Inc. (GE Healthcare)
4.7. Combimatrix Corp.
4.8. Foundation One
4.9. Insight Genetics, Inc.
4.10. InVivoScribe Technologies, Inc.
4.11. Ipsogen (Qiagen)
4.12. Münchner Leukämie Labor
4.13. Sequenta, Inc.
4.14. Signature Genomics
4.15. SkylineDx BV

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/

Global Antithrombotic Drugs Market US$ 27.5 Billion by 2021
The global antithrombotic drugs market expected to reach US$ 27.5 billion by 2021, growing at CAGR 1.9% over the forecast period 2017-2021.
Antithrombotic drugs in routine use include antiplatelet drugs (aspirin, clopidogrel, and glycoprotein IIb/IIIa receptor antagonists) and anticoagulants (unfractionated and low molecular weight heparin, warfarin, and direct thrombin inhibitors). The use of antithrombotic therapy in acute coronary syndromes has reduced the incidence of death and Q wave myocardial infarction dramatically in recent years. Antithrombotic drugs are categorized into three broad types: platelet aggregation inhibitors (PAIs), fibrinolytics and anticoagulants. Antithrombotic therapy has reduced the risk of blood clots in leg veins (also known as deep-vein thrombosis or DVT), a condition that can lead to death from pulmonary embolism by more than 70 percent. And most importantly, it has markedly reduced death from heart attacks, the risk of stroke in people with heart irregularities (atrial fibrillation), and the risk of major stroke in patients with mini-strokes.

Visit Antithrombotic Drugs Market by Drug Type - Platelet Aggregation Inhibitors (PAIs); Fibrinolytics; Anticoagulants - Low-Molecular-Weight Heparins (LMWHs), Vitamin K Antagonists (VKAs), Direct Thrombin Inhibitors (DTIs), Direct Factor Xa Inhibitors (FXa); Other Antithrombotic Agents and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/

The global antithrombotic drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global antithrombotic drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global antithrombotic drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global antithrombotic drugs market and profiled in this report include Armetheon, Armetheon, Bayer, Boehringer Ingelheim, Bristol-Myers Squib, Daiichi Sankyo, D Pharm, Endotis Pharma, Janssen, Lundbeck, Merck & Co., Pfizer, Portola Pharmaceuticals, Regado Biosciences, Roche, TeaRx, and The Medicines Company.

1. Drug Type
1.1. Platelet Aggregation Inhibitors (PAIs)
1.2. Fibrinolytics
1.3. Anticoagulants
1.3.1. Low-Molecular-Weight Heparins (LMWHs)
1.3.2. Vitamin K Antagonists (VKAs)
1.3.3. Direct Thrombin Inhibitors (DTIs)
1.3.4. Direct Factor Xa Inhibitors (FXa)
1.4. Other Antithrombotic Agents

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Armetheon
3.2. Armetheon
3.3. Bayer
3.4. Boehringer Ingelheim
3.5. Bristol-Myers Squib
3.6. Daiichi Sankyo
3.7. D Pharm
3.8. Endotis Pharma
3.9. Janssen
3.10. Lundbeck
3.11. Merck & Co.
3.12. Pfizer
3.13. Portola Pharmaceuticals
3.14. Regado Biosciences
3.15. Roche
3.16. TeaRx
3.17. The Medicines Company

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/

Global Cystic Fibrosis (CF) Drugs Market US$ 5.2 Billion by 2021
The global cystic fibrosis (CF) drugs market expected to reach US$ 5.2 billion by 2021, growing at CAGR 14.9% over the forecast period 2017-2021.
The CF treatment options include: airway-clearance techniques and medications to clear mucus from the lungs; proactive treatment of infections; pancreatic enzyme replacement therapy (PERT); optimal nutrition; and an active lifestyle. Ivacaftor (Kalydeco) was the first drug approved by the US Food and Drug Administration (FDA) in 2012, however it remains very expensive.

Visit the global cystic fibrosis drugs market by drug class – anti-infectives, CF transmembrane conductance regulator (CFTR) modulators, mucolytics, and pancreatic enzyme replacement therapy (PERT), by geography and forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/

The global cystic fibrosis drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global cystic fibrosis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global cystic fibrosis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global cystic fibrosis drugs market and profiled in this report include AbbVie, AlgiPharma, Aptalis Pharma, Cystic Fibrosis Foundation (CFF), Eli Lilly, Genentech (Roche), Grifols, Insmed, KaloBios Pharmaceuticals, N30 Pharmaceuticals, NovaBiotics, Novartis, Pharmaxis, PTC Therapeutics, Savara Pharmaceuticals, UK Cystic Fibrosis Gene Therapy Consortium (CFGTC), and Vertex Pharmaceuticals.

1. Drug Class
1.1. Anti-infectives
1.2. CF Transmembrane Conductance Regulator (CFTR) modulators
1.3. Mucolytics
1.4. Pancreatic Enzyme Replacement Therapy (PERT)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. AbbVie
3.2. AlgiPharma
3.3. Aptalis Pharma
3.4. Cystic Fibrosis Foundation (CFF)
3.5. Eli Lilly
3.6. Genentech (Roche)
3.7. Grifols
3.8. Insmed
3.9. KaloBios Pharmaceuticals
3.10. N30 Pharmaceuticals
3.11. NovaBiotics
3.12. Novartis
3.13. Pharmaxis
3.14. PTC Therapeutics
3.15. Savara Pharmaceuticals
3.16. UK Cystic Fibrosis Gene Therapy Consortium (CFGTC)
3.17. Vertex Pharmaceuticals

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/

Global Systemic Lupus Erythematosus and Lupus Nephritis Drugs Market US$ 1.8 Billion by 2021
The global systemic lupus erythematosus and lupus nephritis drugs market expected to reach US$ 1.8 billion by 2021, growing at CAGR 7.4% over the forecast period 2017-2021.
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by systemic chronic inflammation that can affect multiple major organ systems. A major contributor to morbidity and mortality among patients with SLE is renal involvement, known as lupus nephritis (LN).

Visit The global systemic lupus erythematosus and lupus nephritis drugs market segmentation is based on drug class (antimalarials, biologics, immunosuppressives, steroids), by geography and forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/

The global systemic lupus erythematosus and lupus nephritis drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global systemic lupus erythematosus and lupus nephritis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global systemic lupus erythematosus and lupus nephritis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global systemic lupus erythematosus and lupus nephritis drugs market and profiled in this report include Active Biotech, Anthera, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Galapagos NV, Genentech (Roche), GlaxoSmithKline, Immunomedics, ImmuPharma, Invion, Johnson & Johnson, MedImmune, Merck Serono, Pfizer, SuppreMol, Teva Pharmaceutical Industries Ltd., and UCB (Union Chimique Belge).

1. Drug Class
1.1. Antimalarials
1.2. Biologics
1.3. Immunosuppressives
1.4. Steroids

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Active Biotech
3.2. Anthera
3.3. Biogen Idec
3.4. Bristol-Myers Squibb
3.5. Eli Lilly
3.6. Galapagos NV
3.7. Genentech (Roche)
3.8. GlaxoSmithKline
3.9. Immunomedics
3.10. ImmuPharma
3.11. Invion
3.12. Johnson & Johnson
3.13. MedImmune
3.14. Merck Serono
3.15. Pfizer
3.16. SuppreMol
3.17. Teva Pharmaceutical Industries Ltd.
3.18. UCB (Union Chimique Belge)

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/

Global Chronic Lymphocytic Leukemia (CLL) Drugs Market US$ 5.9 Billion by 2021
The global chronic lymphocytic leukemia (CLL) drugs market expected to reach US$ 5.9 billion by 2021, growing at CAGR 13.6% over the forecast period 2017-2021.
Chronic lymphocytic leukemia is one of the most common forms of leukemia. American Cancer Society estimates about 20,110 new cases of chronic lymphocytic leukemia in the United States for 2017. CLL accounts for about one-quarter of the new cases of leukemia. The main treatments used includes chemotherapy, monoclonal antibodies, targeted therapy, supportive care, and stem cell transplant. There are 2 general categories of systemic therapy used for CLL: chemotherapy and targeted therapy.

Visit Chronic Lymphocytic Leukemia Drugs Market by Drug Class (Brand) – Chemotherapy (Bendamustine); Kinase Inhibitors - Ibrutinib (Imbruvica), Idelalisib (Zydelig); Monoclonal Antibodies - Obinutuzumab (Gazyva), Ofatumumab (Arzerra), Rituximab (Rituxan) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/

The global chronic lymphocytic leukemia drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global chronic lymphocytic leukemia drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global chronic lymphocytic leukemia drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global chronic lymphocytic leukemia drugs market and profiled in this report include AbbVie, Angstrom Pharmaceuticals, AstraZeneca, Celgene, Cyclacel, Gilead Sciences, Infinity, MedImmune, MorphoSys, Novartis, NOXXON Pharma, Roche, Teva Pharmaceutical Industries Ltd., and TG Therapeutics.

1. Drug Class (Brand)
1.1. Chemotherapy
1.1.1. Bendamustine
1.2. Kinase Inhibitors
1.2.1. Ibrutinib (Imbruvica)
1.2.2. Idelalisib (Zydelig)
1.3. Monoclonal Antibodies
1.3.1. Obinutuzumab (Gazyva)
1.3.2. Ofatumumab (Arzerra)
1.3.3. Rituximab (Rituxan)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. AbbVie
3.2. Angstrom Pharmaceuticals
3.3. AstraZeneca
3.4. Celgene
3.5. Cyclacel
3.6. Gilead Sciences
3.7. Infinity
3.8. MedImmune
3.9. MorphoSys
3.10. Novartis
3.11. NOXXON Pharma
3.12. Roche
3.13. Teva Pharmaceutical Industries Ltd.
3.14. TG Therapeutics

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/

Post has attachment
Global Osteoporosis Diagnostics Market US$ 395 Million by 2021
Osteoporosis disease is characterized by thinning and deterioration of bone tissue with loss of calcification and density, and it can progress over time. Women and older adults are more at risk for developing osteoporosis. Heredity, low body weight, and chronic use of certain medications (such as steroids) are also risk factors for the disease.

Visit global osteoporosis diagnostics market by product type (bone densitometry systems, and bone remodeling biochemical marker tests), by geography and forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/

The global osteoporosis diagnostics market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global osteoporosis diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global osteoporosis diagnostics market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global osteoporosis diagnostics market and profiled in this report include Alere, Inc., BeamMed, Beckman Coulter, Inc., CompuMed, Inc., Diagnostic Medical Systems, Furuno Electric Company, GE Healthcare, Hitachi Medical Systems, Hologic, Immunodiagnostic Systems Ltd., Orion Diagnostica, Quest Diagnostics, Inc., Quidel Corp., Roche Diagnostics, Sectra AB, and Swissray International, Inc.

1. Product Type
1.1. Bone Densitometry Systems
1.2. Bone Remodeling Biochemical Marker Tests

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Alere, Inc.
3.2. BeamMed
3.3. Beckman Coulter, Inc.
3.4. CompuMed, Inc.
3.5. Diagnostic Medical Systems
3.6. Furuno Electric Company
3.7. GE Healthcare
3.8. Hitachi Medical Systems
3.9. Hologic
3.10. Immunodiagnostic Systems Ltd.
3.11. Orion Diagnostica
3.12. Quest Diagnostics, Inc.
3.13. Quidel Corp.
3.14. Roche Diagnostics
3.15. Sectra AB
3.16. Swissray International, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/

Global osteosynthesis devices market type of device used (internal fixation devices – intramedullary rods and nails, screws and plates, spinal fixation devices, wires and pins; external fixation devices – fracture fixation devices, radius fracture, tibia fracture and pelvis fracture fixation devices, bone lengthening devices, etc.), materials used (degradable and non-degradable). https://www.ihealthcareanalyst.com/report/osteosynthesis-devices-market/

Global osteoporosis drugs market by drug classes (bisphosphonates, calcitonin, parathyroid hormone therapy drugs, RANK ligand inhibitors, selective estrogen receptor modulators, etc.), clinical pipeline analysis of phase 1, 2 and 3 drugs (Odanacatib, Romosozumab, etc.). https://www.ihealthcareanalyst.com/report/osteoporosis-drugs-market/

Top 10 Medical Device Areas Analysis (2014-2020) - According to a recent world preview report (2015) by EvaluateMedTech indicated the total value of the global medical devices market with sales in 2014 at $375.2bn and it is expected to reach $477.5bn by 2020, growing at an annual rate of 4.1% over the next five years till 2020.  In vitro diagnostics (IVD) would be the number one medical device area in 2020, achieving sales of $67.3bn or a 14.1% share of the medical device industry. Interestingly, in addition to being the top area it is also the second fastest-growing area in the top 15, with a 5.1% CAGR between 2014 and 2020. Neurology medical devices takes the top spot as the fastest-growing device area, with sales set to expand at an annual rate of 6.9% between 2014 and 2020, reaching $9.5bn in 2020.



Medical Devices Area
Sales (US$ Bn)
CAGR (2014-2020)
Market Share (%)


2014
2020
2014
2020


In Vitro Diagnostics (IVD)
49.9
67.3
5.1%
13.3%
14.1%


Cardiology
41.9
54.2
4.4%
11.2%
11.4%


Orthopedics
34.8
42
3.2%
9.3%
8.8%


Diagnostic Imaging
35.6
40.9
2.3%
9.5%
8.6%


Ophthalmics
25.6
33.7
4.7%
6.8%
7.1%


General & Plastic Surgery
19.4
24.6
4.0%
5.2%
5.1%


Drug Delivery
18.6
22.3
3.1%
4.9%
4.7%


Endoscopy
16.3
21.5
4.8%
4.3%
4.5%


Dental
12.9
16.5
4.2%
3.4%
3.5%


Wound Management
12.9
15.8
3.4%
3.4%
3.3%


Diabetic Care
11.5
14.4
3.8%
3.1%
3.0%


Nephrology
11.3
13.5
3.1%
3.0%
2.8%


Ear, Nose  & Throat (ENT)
8.5
11
4.3%
2.3%
2.3%


General Hospital & Healthcare
8.9
10.9
3.4%
2.4%
2.3%


Neurology
6.4
9.5
6.9%
1.7%
2.0%


Other
60.8
79.5
4.6%
16.2%
16.7%



Top 10 Medical Device Areas Analysis (2014-2020)
Source: EvaluateMedTech® September 2015
- http://www.ihealthcareanalyst.com/medical-device-areas-analysis/

Revenue Forecasting for New Pharmaceutical Drugs - The three ways of estimating market size (product revenue) include bottom up market analysis, analyst reports and research reports, and analogue (similar products) markets. The best approach would be to have a good bottom up model and cross checking the market estimation results with the external reports and similar product revenues.
In case of new pharmaceutical drugs, the market size and revenue estimation (bottom up approach) involves the following steps:

Potential Market Size Estimation

Total Population, Population in Target Markets
Incidence/Prevalence


Addressable Market Size Estimation

% Diagnosed
% Treated for Disease


Penetration, Pricing Studies, Competitive Analysis, Compliance Analysis, Reimbursement Analysis and Utilization Patterns Analysis

% Prescription of Drug
Price per Day of Drug
Actual Ave Days Used



There are four important ways in which a novel drug can take up considerable share in the market:

Better efficacy and/or safety than current treatments
Synergistic with existing treatments
Better outcomes in certain patient subgroups
Better marketing in the face of generics

Defining Pharmaceuticals New Drug Market:
 1. Estimation of Incidence and Prevalence

Prevalence:

Total number of potential customers at any one point in time
Best for products purchased by same customer on a recurring basis (e.g. chronic Rx)


Incidence:

Number of new potential customers each year
Best for products treating one time acute event (e.g. heart attack)




Identification of Segments


All potential customers are not alike
Segmentation helps refine penetration and share forecasts
It also allows to refine estimates and focus efforts by identifying “early adopters”

For example:

Severely affected patients (25% of the market)
Moderately affected
Mildly affected






Analysis of Change Over Time


Customer base and segmentation are influenced by factors that change over time
Growth drivers analysis provides insight into changing and/or emerging markets

Building Penetration Scenarios:
Penetration is usually the main driver of revenue forecasts. There are a few different means to estimate the peak penetration that a new product can be expected to achieve:

Historical penetration of comparable products
Objective comparisons versus currently available treatments (efficacy, safety, convenience)
Physician interviews to gauge acceptance and potential use versus competing treatments (preference share analysis)
Analysis of likely reimbursement and factors related to achieving reimbursement from key payer groups
Mapping of commercial effort into physician prescribing behavior (companies often use IMS analysis)
Almost all “bottoms up” approaches to penetration analysis tend to overestimate penetration in practice. Preference analysis tends to do a poor job of predicting actual prescribing behavior in the face of detailing and sampling
Comparison versus pipeline products and relative timing to market

Research Methodology for Market Size Estimation and Penetration Analysis:

Primary market research (Structured Interviews) to determine usage and dependence on pricing

By Physician Segment
By Disease State (e.g., first line, second line)


Historical analysis of impact of order of entry1,2
Penetration Analysis to understand prescriber concentration, sales force design, prescribing behavior and reimbursement positioning

References:

Kalyanaram,”The order of entry effect in prescription (Rx) and over-the-counter (OTC) pharmaceutical drugs,” International Journal of Pharmaceutical and Healthcare Marketing, 2008, pp. 35-46.
Hans Bauer and Marc Fischer, “Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products,” International Business Review, 2000, 703-725.

 
- http://www.ihealthcareanalyst.com/revenue-forecasting-new-pharma-drugs/
Wait while more posts are being loaded